ACR experts break down MIPS, MVPs & the RISE registry, helping clinicians understand quality reporting requirements for 2026 & beyond.
Approaches to the Management of SLE During Pregnancy
At this ACR Convergence 2025 session, experts discussed disease management considerations to optimize outcomes in pregnant patients with SLE.
Complicated Cases Discussed in Pediatric Thieves Market
At this ACR Convergence 2025 session, clinicians discussed complex and difficult-to-diagnose pediatric cases.
Workforce Solutions
Three experts discussed novel and practical strategies and resources that rheumatology clinics can use to improve the referral process, screening times and patients access to care.
Advances in Giant Cell Arteritis
Dr. Philip Seo highlights the latest research into the assessment and treatment of giant cell arteritis presented during ACR Convergence 2025.
ACR Releases New Guideline for Management of SLE at ACR 2025
Updating the last iteration in 1999, the new ACR Guideline for Management of SLE was unveiled at ACR Convergence 2025, providing rheumatologists an organ-based approach for therapeutic options for specific lupus manifestations.
Complementary Medicine Meets Rheumatology: New Ways to Reduce Inflammation
At this ACR Convergence 2025 session, the speaker highlighted ways complementary and alternative medicine can be used alongside traditional medical treatments.
ARP Year in Review: Updates in Advanced Practice, Epidemiology & Rehabilitation
Three experts discussed recent notable research of interest to rheumatology professionals across a range of topics.
Secrets & Pearls of Rheumatology at ACR Convergence 2025
Two clinical diagnosticians presented their pearls of wisdom for clinical rheumatologists to take forward when managing patients from the clinics to the hospital wards.
3 AC&R Study Summaries: RA & Frailty, Hydroxychloroquine Can Protect Kidneys in Lupus Nephritis, & PT for Knee OA
Research on PT for knee OA, HCQ’s protective role in lupus nephritis & the link between RA disease activity & frailty.